30 closest matches · ranked by relevance
Zollinger-Ellison Syndrome · Multiple Endocrine Neoplasia
Primary: Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. — 72 participants
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Gastric Ulcer (GU) · Duodenal Ulcer (DU) · Anastomotic Ulcer (AU)
Primary: Disappearance of Heartburn at Week 8 by Patient Diaries — 2; 0; 0; 1 Participants
Cancer of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Cancer of the Stomach
Primary: Maximum Tolerated Dose of Vandetanib — 100 milligrams
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Endocrine Tumors
Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Multiple Endocrine Neoplasia Type 1 · Pancreatic Neuroendocrine Carcinoma
Primary: Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 9.5 percentage of participants
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 22; 100 Participants
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Esophageal Cancer
Primary: Progression-free Survival Rate — 7 weeks
Gastrointestinal Carcinoid Tumor · Islet Cell Tumor · Neoplastic Syndrome
Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Barrett's Esophagus
Primary: Mean Ki67 Expression — 35.6; 307.8 cells/mm2
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs) — 6; 0; 5 Participants
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Disease Control Rate (DCR) After 6 Months — 73.5 percentage of subjects
Pancreatic Alpha Cell Carcinoma · Pancreatic Beta Islet Cell Carcinoma · Pancreatic Delta Cell Carcinoma
Primary: Determine the Maximum Tolerated Dose (MTD) of Temozolomide in Combination With 400 mg Pazopanib in Patients With Advanced Pancreatic Neuroendocrine Tumor (PNET) in Phase…
Esophageal Cancer
Primary: The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or…
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Stage IV Pancreatic Cancer
Primary: Maximum Tolerated Dose Determination — 6 mg/kg IMC-A12
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Dumping Syndrome
Primary: Response Rate in Plasma Glucose Level — 60.5 percentage of participants
Pancreatic Adenocarcinoma
Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants